Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis

Cancer cells exploit CD47 overexpression to inhibit phagocytic elimination and neoantigen processing via the myeloid CD47-SIRPα axis and thereby indirectly evade adaptive T cell immunity. Here, we report on a hitherto unrecognized direct immunoinhibitory feature of cancer cell-expressed CD47. We unc...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Mark A.J.M. Hendriks, Isabel Britsch, Xiurong Ke, Anne P. van Wijngarden, Douwe F. Samplonius, Emily M. Ploeg, Wijnand Helfrich
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Subjects:	cd47 resistance t cell-induced cytotoxicity bispecific antibody cancer immunotherapy
Online Access:	http://dx.doi.org/10.1080/2162402X.2021.2005344